文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

结核分枝杆菌复合群对普托马尼固有敏感性的古老与近期差异

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

研究在六家实验室用MGIT系统测定356株结核分枝杆菌复合群(MTBC)对普托马尼的MIC,以建立流行病学折点,并用WGS分析敏感性差异的遗传基础。结果显示谱系1的MIC第99百分位为2 mg/L,高于其余结核分枝杆菌谱系的0.5 mg/L;6株菌近期独立进化出较高MIC(≥8 mg/L)。作者认为EMA设定的MGIT暂定临界浓度1 mg/L须重新评估。

要点

  • 谱系1结核分枝杆菌对普托马尼的MIC第99百分位为2 mg/L,高于谱系2、3、4、7的0.5 mg/L。
  • 6株结核分枝杆菌近期独立进化出较高MIC(≥8 mg/L),可能由已知普托马尼耐药基因突变所致。
  • 作者认为EMA设定的MGIT暂定临界浓度1 mg/L须重新评估。

核心结论

  • 结核分枝杆菌复合群对普托马尼的敏感性存在古老谱系差异,谱系1的MIC第99百分位为2 mg/L,高于其余结核分枝杆菌谱系的0.5 mg/L。
  • 近期独立进化出的较高MIC(≥8 mg/L)可能由已知普托马尼耐药基因突变所致。
  • 作者认为EMA设定的MGIT暂定临界浓度1 mg/L须重新评估,并强调药物临床开发与药敏折点定义需考虑MTBC的全球多样性。

研究设计与样本

  • 在六家实验室使用Becton Dickinson MGIT系统,测定356株系统发育多样的MTBC菌株对普托马尼的MIC,以建立流行病学折点。
  • 将MIC与WGS数据关联,研究普托马尼敏感性差异的遗传基础。

主要发现

  • 谱系1结核分枝杆菌对普托马尼的MIC第99百分位为2 mg/L,谱系2、3、4、7的MIC第99百分位为0.5 mg/L。
  • 谱系1估计占全球结核病病例的28%。
  • 6株不同的结核分枝杆菌近期独立进化出较高MIC(≥8 mg/L),可能由已知普托马尼耐药基因突变所致。

关键数值与推荐

  • EMA设定的MGIT暂定临界浓度为1 mg/L。
  • 谱系1结核分枝杆菌的MIC第99百分位为2 mg/L。
  • 谱系2、3、4、7结核分枝杆菌的MIC第99百分位为0.5 mg/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop a robust phenotypic antimicrobial susceptibility testing (AST) method with a correctly set breakpoint for pretomanid (Pa), the most recently approved anti-tuberculosis drug. METHODS: The Becton Dickinson Mycobacterial Growth Indicator Tube™ (MGIT) system was used at six laboratories to determine the MICs of a phylogenetically diverse collection of 356 Mycobacterium tuberculosis complex (MTBC) strains to establish the epidemiological cut-off value for pretomanid. MICs were correlated with WGS data to study the genetic basis of differences in the susceptibility to pretomanid. RESULTS: We observed ancient differences in the susceptibility to pretomanid among various members of MTBC. Most notably, lineage 1 of M. tuberculosis, which is estimated to account for 28% of tuberculosis cases globally, was less susceptible than lineages 2, 3, 4 and 7 of M. tuberculosis, resulting in a 99th percentile of 2 mg/L for lineage 1 compared with 0.5 mg/L for the remaining M. tuberculosis lineages. Moreover, we observed that higher MICs (≥8 mg/L), which probably confer resistance, had recently evolved independently in six different M. tuberculosis strains. Unlike the aforementioned ancient differences in susceptibility, these recent differences were likely caused by mutations in the known pretomanid resistance genes. CONCLUSIONS: In light of these findings, the provisional critical concentration of 1 mg/L for MGIT set by EMA must be re-evaluated. More broadly, these findings underline the importance of considering the global diversity of MTBC during clinical development of drugs and when defining breakpoints for AST.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Bateson A, Ortiz Canseco J, McHugh TD, et al. Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. J Antimicrob Chemother. 2022. PMID: 35260883. doi:10.1093/jac/dkac070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。